Human genetic evidence supports fibroblast growth factor 21 as a novel therapeutic target for gout.

IF 4.7 2区医学 Q1 RHEUMATOLOGY

Rheumatology Pub Date : 2024-10-01 DOI:10.1093/rheumatology/keae210

Sizheng Steven Zhao, Daniel J Cuthbertson, Uazman Alam

引用次数: 0

查看原文本刊更多论文

人类遗传学证据支持成纤维细胞生长因子 21 (FGF21) 成为痛风的新型治疗靶点。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Rheumatology 医学-风湿病学

CiteScore

9.40

自引率

7.30%

发文量

1091

审稿时长

2 months

期刊介绍： Rheumatology strives to support research and discovery by publishing the highest quality original scientific papers with a focus on basic, clinical and translational research. The journal’s subject areas cover a wide range of paediatric and adult rheumatological conditions from an international perspective. It is an official journal of the British Society for Rheumatology, published by Oxford University Press. Rheumatology publishes original articles, reviews, editorials, guidelines, concise reports, meta-analyses, original case reports, clinical vignettes, letters and matters arising from published material. The journal takes pride in serving the global rheumatology community, with a focus on high societal impact in the form of podcasts, videos and extended social media presence, and utilizing metrics such as Altmetric. Keep up to date by following the journal on Twitter @RheumJnl.